Published on 21/12/2025
Establishing Robust Sample Re-Analysis Procedures for Regulatory Compliance
Introduction: Why Re-Analysis Is Critical in Bioanalytical Testing
Bioanalytical laboratories supporting clinical trials routinely encounter scenarios where test results may be flagged for potential re-analysis. These may include unexpected values, assay drift, out-of-specification (OOS) results, or stability-related deviations. Re-analysis refers to repeating the sample test using the same validated method to confirm or clarify the original result.
Regulatory agencies such as the FDA, EMA, and MHRA closely scrutinize re-analysis practices, especially during inspections. Improper justification or lack of documentation for re-analysis can lead to serious data integrity concerns. Therefore, laboratories must define strict, transparent, and auditable procedures to govern sample re-analysis throughout the trial lifecycle.
Regulatory Expectations for Sample Re-Analysis
Several global regulatory bodies offer guidance on how and when sample re-analysis should be performed:
- FDA’s Bioanalytical Method Validation Guidance (2018): Re-analysis must be scientifically justified and pre-defined in SOPs or protocol.
- EMA Guideline on Bioanalytical
Agencies expect a clear decision-making tree for determining when re-analysis is permitted, and how results are handled and reported.
Triggers for Sample Re-Analysis
The following conditions may justify re-analysis:
- Instrument failure or run interruption during original analysis
- Out-of-range QC samples in the same batch
- Suspected carryover contamination
- Data transcription or calculation errors (prior to reporting)
- Subject sample result inconsistent with clinical context
- Stability-related concerns due to freeze-thaw cycles
- Missing or unreadable chromatographic peaks
Re-analysis should not be used to obtain desired results or artificially remove outliers. It is a scientific and quality assurance mechanism — not a data manipulation tool.
Decision Flowchart for Re-Analysis (Illustrative)
| Trigger | Re-Analysis Justified? | Action |
|---|---|---|
| QC failure in batch | Yes | Repeat full batch with new QC |
| Calculation error in report | No | Correct data without re-test |
| Unusual low result | Only with scientific rationale | Request review from PI or QA |
| Analyst observed contamination | Yes | Document root cause, re-analyze sample |
Re-Analysis SOP Elements
Laboratories must maintain a dedicated SOP for re-analysis, including:
- Definitions: Clarify difference between re-analysis, repeat testing, and re-injection
- Pre-authorization: Define when analyst must seek QA approval
- Documentation: Maintain audit trail including chromatograms, reason for re-analysis, and raw data
- Data Handling: Define whether original or repeat value is reported, and justification
- QC Inclusion: Whether re-analysis requires full batch or single sample processing
CAPA for Improper Re-Analysis
Regulatory audits have identified several compliance issues related to improper re-analysis:
- Missing documentation for re-analysis rationale
- Multiple retests until desired value is achieved
- Unapproved SOP deviations
- Analyst-initiated re-tests without QA review
In such cases, CAPA should include:
- Retraining of analysts on re-analysis criteria
- Revision of SOP to strengthen approval workflow
- Retrospective audit of historical re-analyses
- Inclusion of re-analysis justification in sponsor audit trail
Sample Case: MHRA Audit Observation on Re-Analysis
During an MHRA inspection of a Phase III oncology trial, the auditor noted that 18% of plasma samples were re-analyzed due to “unexpectedly high concentration.” Upon review, no scientific or protocol-based rationale was documented, and analysts had used their own discretion.
The site received a critical finding. CAPA included a ban on discretionary re-analysis, mandatory documentation fields in the LIMS system, and routine QA review of all flagged samples.
Inspection Readiness Tips
To demonstrate compliance with sample re-analysis practices, labs should:
- Maintain centralized logs of all re-analyzed samples, linked to original results
- Ensure that re-analysis is traceable in audit trail and includes date, analyst, method, and batch ID
- Flag re-analysis in sponsor data listings (e.g., eCRF or central lab file)
- Retain original data — never overwrite with repeat value unless SOP permits
Role of Data Management in Re-Analysis Tracking
Integration with data management platforms (e.g., CDMS or LIMS) can streamline re-analysis monitoring. Automated triggers for re-analysis and electronic CAPA workflows allow:
- Faster resolution of flagged results
- Documentation of justification in real time
- Preventing unauthorized retesting through system validation
Conclusion: Making Re-Analysis Defensible and Audit-Proof
In regulated clinical trials, re-analysis is a necessary quality control tool but must be executed with extreme discipline. It cannot be used to “fix” data or support bias-driven decisions. Instead, it should be a structured, documented, and statistically defensible activity that strengthens overall data quality.
Sponsors, CROs, and laboratories must invest in clear SOPs, QA oversight, analyst training, and audit trail integrity. When these systems are in place, sample re-analysis becomes a regulatory strength — not a vulnerability.